ArticleCancer cell2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.
- Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis.Annals of medicine · 2026Pooled it
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4Cell reports methods · 2026Article
- Anti-PD-1 Treatment Restores Effector Function in Exhausted-like T Cells from Malignant Ascites of Ovarian Cancer Patients.Cancers · 2026Article
- Macrophage Plasticity in Cancer Therapy: Function, Timing, and Tradeoffs.International journal of molecular sciences · 2026Review
- Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.Bioactive materials · 2026Article
- Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- MiR-139 modulates CD8iScience · 2026Article
- Article
- Advances in immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2026Review
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.Signal transduction and targeted therapy · 2026Article
- Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.Blood cancer discovery · 2026Article
- Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer.Stem cell research & therapy · 2026Article
- Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8Research square · 2026Article
- CD4Journal for immunotherapy of cancer · 2026Article
- The Role of B Cells in Tumorigenesis and Immunotherapy.Immune network · 2026Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
36 authors at 10 institutions in 5 countries.
Jaikumar DuraiswamyOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Riccardo TurriniLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Aspram MinasyanLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
David BarrasLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland; Bioinformatics Core Facility, Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Isaac CrespoLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Alizée J GrimmLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Julia CasadoResearch Program of Systems Oncology, University of Helsinki, 00014 Helsinki, Finland.
Raphael GenoletLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Fabrizio BenedettiLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Alexandre WickyCenter for Precision Oncology, Department of Oncology, CHUV, 1011 Lausanne, Switzerland.
Kalliopi IoannidouLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Wilson CastroLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Christopher NealLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Amandine MoriotLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Stéphanie Renaud-TissotLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, CHUV, 1011 Lausanne, Switzerland.
Victor AnstettLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Noémie FahrLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Janos L TanyiOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Monika A EivaOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Connor A JacobsonHarvard Ludwig Center, Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Kathleen T MontoneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marie Christine Wulff WestergaardNational Center for Cancer Immune Therapy, Copenhagen University Hospital, 2730 Herlev, Denmark.
Inge Marie SvaneNational Center for Cancer Immune Therapy, Copenhagen University Hospital, 2730 Herlev, Denmark.
Lana E KandalaftLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, CHUV, 1011 Lausanne, Switzerland.
Mauro DelorenziBioinformatics Core Facility, Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland; Department of Oncology, UNIL, 1011 Lausanne, Switzerland.
Peter K SorgerHarvard Ludwig Center, Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Anniina FärkkiläResearch Program of Systems Oncology, University of Helsinki, 00014 Helsinki, Finland; Department of Obstetrics and Gynecology, Helsinki University Hospital, 00014 Helsinki, Finland.
Olivier MichielinCenter for Precision Oncology, Department of Oncology, CHUV, 1011 Lausanne, Switzerland.
Vincent ZoeteLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Santiago J CarmonaLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Periklis G Foukas2nd Department of Pathology, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Daniel J PowellOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sylvie RusakiewiczLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, CHUV, 1011 Lausanne, Switzerland.
Marie-Agnès DouceyLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Denarda Dangaj LanitiLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
George CoukosLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland. Electronic address: george.coukos@chuv.ch.
Ludwig Cancer Research · CHUniversity of Pennsylvania · USCancer Research Center · USHarvard University · USHerlev Hospital · DKPrecision for Medicine (United States) · USSIB Swiss Institute of Bioinformatics · CHUniversity of Helsinki · FINational and Kapodistrian University of Athens · GRUniversity Hospital of Lausanne · CH
Funding
Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DALY, MARY BERYL, REBBECK, TIMOTHY R · 1999 to 2013
$33.6MUsing Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ronny I DRAPKIN, IE-MING SHIH · 2018 to 2026
$20.5MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2018 to 2022
$10.8MQuantitative control of CAR T cells via image-guided delivery and monitoringR01EB026892 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI FARWELL, MICHAEL DAVID, POWELL, DANIEL J. · 2018 to 2021
$2.6MEndothelial Regulation of T Cell Homing in Ovarian CarcinomaR01CA098951 · NCI · UNIVERSITY OF PENNSYLVANIA · PI COUKOS, GEORGE · 2003 to 2007
$1.5MVascular Leukocytes Induce Treg in TumorsR01CA116779 · NCI · UNIVERSITY OF PENNSYLVANIA · PI COUKOS, GEORGE · 2006 to 2010
$1.5MNCI NIH HHS P50 CA083638NCI NIH HHS R01 CA098951NCI NIH HHS R01 CA116779NCI NIH HHS U54 CA225088NIBIB NIH HHS R01 EB026892NIGMS NIH HHS P20 GM130423
Abstract
The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that tumor-specific CD8
Indexed as
Antigen-Presenting CellsCD28 AntigensHumansImmune Checkpoint InhibitorsMyeloid CellsNeoplasmsStem Cell NicheCD28 AntigensImmune Checkpoint InhibitorsCD28CD40CTLA-4dendritic cellexhaustionmyeloid nicheovarianPD-1TILtumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.